細(xì)胞周期素D1(CCND1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Cyclin D1 (CCND1)
CCN-D1; BCL1; PRAD1; U21B31; G1/S-Specific Cyclin-D1; Parathyroid Adenomatosis 1; B-Cell CLL/Lymphoma 1; G1/S-Specific Cyclin D1; PRAD1 oncogene
- 編號USEA585Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3h
- 檢測范圍0.156-10ng/mL
- 靈敏度最小可檢測劑量小于等于0.058ng/mL.
- 樣本類型tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1361 ¥ 1944 ¥ 8748 ¥ 16524 ¥ 136080
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測細(xì)胞周期素D1(CCND1)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個(gè)樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將細(xì)胞周期素D1(CCND1)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的細(xì)胞周期素D1(CCND1)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的細(xì)胞周期素D1(CCND1)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的細(xì)胞周期素D1(CCND1)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA585Mu01 | 細(xì)胞周期素D1(CCND1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA585Mu02 | 細(xì)胞周期素D1(CCND1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA585Mu02 | 細(xì)胞周期素D1(CCND1)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAA585Mu01 | 細(xì)胞周期素D1(CCND1)多克隆抗體 | WB |
| ULAA585Mu71 | 細(xì)胞周期素D1(CCND1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| ULAA585Mu81 | 細(xì)胞周期素D1(CCND1)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| USEA585Mu | 細(xì)胞周期素D1(CCND1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA585Mu | 細(xì)胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSA585Mu01 | 細(xì)胞周期素D1(CCND1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Biochemical Pharmacology | Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells [ScienceDirect: S0006295211002097] |
| Leukemia & Lymphoma | The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-62 human leukemia cells [Pubmed: 24138332] |
| The Journal of Clinical Endocrinology and Metabolism | Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. [Pubmed: 23969186] |
| Nutrition and Cancer | Common Food Additive Carrageenan Stimulates Wnt/ β-Catenin Signaling in Colonic Epithelium by Inhibition of Nucleoredoxin Reduction [Pubmed:24328990] |
| The International Journal of Biochemistry &?Cell?Biology | MicroRNA-149 is epigenetically silenced tumor-suppressive microRNA, involved in cell proliferation and downregulation of AKT1 and cyclin D1 in human … [pubmed:27783537] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA. [pubmed:28533512] |
| Investigational new drugs | Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. [pubmed:29273857] |
| Biochemical Pharmacology | Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase?… [Pubmed:29660315] |
| Apoptosis | Licarin A induces cell death by activation of autophagy and apoptosis in non-small cell lung cancer cells [Pubmed:29468481] |
| Oncology?Reports | Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo [Pubmed:29517106] |
| Oncology Reports | Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo [Pubmed:29517103] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA [Pubmed: 28533512] |
| Middle East Journal of Rehabilitation and Health | Antiapoptotic Effects of Continuous Training and Selenium Consumption on the Liver Tissue of Cadmium-Exposed Rats [Pubmed: 10.5812/mejrh.91278] |
| European journal of medicinal chemistry | Synthesis of novel S-linked dihydroartemisinin derivatives and evaluation of their anticancer activity [Pubmed: 31216504] |
